Catalyst
Slingshot members are tracking this event:
European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| EIGR | Community voting in process | |||||
Additional Information
"We are very pleased with the EMA Committee of Orphan Medicinal Products (COMP) designation of orphan status for ubenimex in PAH," said Joanne Quan, MD, Chief Medical Officer at Eiger. "We will soon begin enrolling the LIBERTY study, a Phase 2, randomized, double-blind, placebo-controlled, multi-center study of ubenimex in PAH patients."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ema, European Medicines Agency, Orphan Drug Status, Ubenimex, Pulmonary Arterial Hypertension, Pah, Liberty Study
